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Multiple myeloma–associated chromosomal
translocation activates orphan snoRNA
ACA11 to suppress oxidative stress
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Seth Crosby,2 Gaofeng Huang,3 Wee Joo Chng,3,4,5,6 Ravi Vij,1 and Michael H. Tomasson1,2
1Division

of Oncology and 2Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.
Loo Lin School of Medicine, 4Department of Haematology-Oncology, National University Cancer Institute of Singapore,
5National University Health System, and 6Cancer Science Institute of Singapore, National University of Singapore, Singapore.

3Yong

The histone methyltransferase WHSC1 (also known as MMSET) is overexpressed in multiple myeloma (MM)
as a result of the t(4;14) chromosomal translocation and in a broad variety of other cancers by unclear mechanisms. Overexpression of WHSC1 did not transform wild-type or tumor-prone primary hematopoietic cells.
We found that ACA11, an orphan box H/ACA class small nucleolar RNA (snoRNA) encoded within an intron
of WHSC1, was highly expressed in t(4;14)-positive MM and other cancers. ACA11 localized to nucleoli and
bound what we believe to be a novel small nuclear ribonucleoprotein (snRNP) complex composed of several proteins involved in postsplicing intron complexes. RNA targets of this uncharacterized snRNP included
snoRNA intermediates hosted within ribosomal protein (RP) genes, and an RP gene signature was strongly
associated with t(4;14) in patients with MM. Expression of ACA11 was sufficient to downregulate RP genes
and other snoRNAs implicated in the control of oxidative stress. ACA11 suppressed oxidative stress, afforded
resistance to chemotherapy, and increased the proliferation of MM cells, demonstrating that ACA11 is a critical target of the t(4;14) translocation in MM and suggesting an oncogenic role in other cancers as well.
Introduction
Multiple myeloma (MM) is an incurable cancer of B-lineage plasma
cells, associated with anemia, renal failure, and cortical bone destruction (1). The recurrent t(4;14)(p16.3;q32.3) chromosomal translocation is detected in 20% of MMs and is associated with shortened
overall survival (2–5). The t(4;14) transposes immunoglobulin heavy
chain region enhancer elements to the 5′ end of the Wolf-Hirschhorn
syndrome candidate 1 gene (WHSC1; also known as MMSET and
NSD2) to drive its ectopic expression (4, 6). WHSC1 encodes 3
protein isoforms that are expressed as a result of alternative splicing (WHSC1-I and WHSC1-II) and an internal promoter (REIIBP;
refs. 6, 7, and Supplemental Figure 1A; supplemental material available
online with this article; doi:10.1172/JCI63051DS1). The WHSC1-II
and REIIBP isoforms contain a SET domain that encodes a histone
methyltransferase (HMT), with activity reported toward H4K20 (8, 9),
H3K36 (10, 11), and H3K27 (12). The HMT activity of WHSC1-II
plays a role in DNA damage responses by recruiting repair factors to
DNA breaks, and this recruitment is dependent upon phosphorylation of WHSC1-II Ser102 by ATM (9, 13).
Three lines of evidence support the role of WHSC1 as an oncogene. First, WHSC1 transcripts are consistently overexpressed in
t(4;14)-positive myelomas, and WHSC1 is also upregulated by
unknown mechanisms in subsets of diverse solid tumor types,
including neuroblastoma, in which high WHSC1 levels are associated with tumor aggressiveness (14–16). Second, transcriptional
deregulation by the HMT encoded by WHSC1 is a plausible mechanism of carcinogenesis. Indeed, H3K36 methyltransferase activity
can be sufficient to initiate malignant transformation (17), and
attractive candidate target genes and pathways have been identiConflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(8):2793–2806. doi:10.1172/JCI63051.

fied for WHSC1 (18, 19). Third, WHSC1 knockdown using shRNAs
decreases cell growth and cell adhesion in MM and neuroblastoma cell lines (8, 10, 15, 20). Knockdown using a variety of shRNA
constructs has established the dependence of transformed cells on
WHSC1 expression, but which WHSC1 isoform is responsible for
cell transformation has not been clearly established.
A difficult-to-explain clue into the cell biology of WHSC1 is
that a subset of t(4;14) patients with MM harbor translocation
breakpoints that result in the overexpression of amino-truncated
WHSC1 proteins. Loss of a nucleolar exclusion signal at the amino
terminus of WHSC1-II causes altered subcellular localization of
these shortened WHSC1 protein products (21), and Ser102 is lost in
these truncations, affecting function of WHSC1 in DNA repair (9).
Yet, the clinical course of t(4;14)-positive patients is independent of
the location of the translocation breakpoints within WHSC1 (21).
Therefore, the precise mechanism by which these different WHSC1
gene products contribute to transformation remains unclear.
To improve our understanding of how the t(4;14) contributes to
myelomagenesis, we evaluated the effects of 3 major WHSC1 isoforms
(WHSC1-I, WHSC1-II, and REIIBP) on hematopoietic cell transformation. Despite an extensive set of reverse genetic experiments,
none of the WHSC1 proteins demonstrated significant pro-growth
effects. These unexpected results prompted us to examine the 4p16.3
breakpoint region in t(4;14)-positive patients with MM for a missing
oncogene. Using RNA tiling arrays, we identified what we believe to
be a novel box H/ACA ncRNA, ACA11, encoded within intron 18–19
of the WHSC1 gene overexpressed in t(4;14)-positive MM and other
cancers. ACA11 is an orphan small nucleolar RNA (snoRNA) that
binds what we believe to be a novel small nuclear ribonucleoprotein
(snRNP) complex in MM cells. Overexpression of ACA11 protected
MM cells from oxidative stress and modulated tumor proliferation,
and knockdown of ACA11 slowed cell proliferation and sensitized
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Figure 1
ACA11 is activated by t(4;14) in MM. (A) Schematic diagram of the
chromosome 4p16.3 tiling oligonucleotide microarray, spanning 430 Kb
across the t(4;14) breakpoint region (breakpoints are indicated by
arrows). Annotated genes are indicated with exon structures. (B) Tiling microarray expression data of representative t(4;14)-positive and
-negative patients with MM. (C) Heat map of t(4;14)-positive (Y; n = 4)
and -negative (N; n = 12) patient samples. (B and C) Numbers indicate
base pairs on chromosome 4 (human genome assembly GRCh37).
(D) Real-time PCR of ACA11 in samples from patients with MM. The
inset shows that ACA11 is significantly associated with t(4;14) status.
Normal, normal plasma cells (n = 10); t(4;14)+, t(4;14)-positive patient
samples (n = 6); t(4;14)–, t(4;14)-negative patient samples (n = 57). (E)
Northern blot of ACA11 expression in human MM cell lines. t(4;14)-positive cell lines included KMS-11, OPM-2, LP-1, and H929 cells; t(4;14)negative cell lines included U266, RPMI8226, and MM.1S cells; and
non-MM cell lines included K562, HeLa, A375, and U1A cells. Loading
controls were 28S and 18S rRNA. (F) ACA11 expression by real-time
PCR is significantly associated with t(4;14) in MM cell lines. qRT-PCR
data in D and F were normalized to the mean of 3 reference genes
(GAPDH, UBC, YWHAZ). Data are presented as mean ± SD, with a
box-whisker plot of minimum-to-maximum values (inset) (n = 3). The
line within the box is the median value. The box represents the first
and third quartiles. The whiskers show the largest and smallest events
within at least 1.5 times the size of the box from the nearest edge.

MM cells to cytotoxic chemotherapy. The discovery of a snoRNA
within WHSC1, a “missing ingredient” overexpressed as a result of the
t(4;14), provides an important molecular target in MM pathogenesis.
Results
WHSC1 cDNAs are not sufficient to induce malignant transformation. Oncogenic activity has been reported for WHSC1 (10, 18, 19), so we sought
to compare the transformation potential of the 3 major WHSC1
isoforms. However, overexpression of WHSC1-I, WHSC1-II, and
REIIBP did not affect NIH/3T3 fibroblast cell proliferation and did
not protect cells from cytotoxic chemotherapy or protect hematopoietic Ba/F3 cells from growth factor withdrawal (Supplemental Figure 1 and data not shown). To assess the effects of WHSC1 isoforms
overexpressed in animals, we developed transgenic strains of mice
expressing WHSC1-I, WHSC1-II, or REIIBP cDNAs under the control
of the B cell–specific immunoglobulin heavy chain enhancer and promoter (Eμ). None of the Eμ-WHSC1 mice had any significant hematopoietic phenotype after 2 years (data not shown). Next, we expressed
WHSC1 isoform transcripts more broadly in primary murine hematopoietic cells using ecotropic retroviruses encoding WHSC1-I,
WHSC1-II, or REIIBP introduced into bone marrow mononuclear
cells transplanted into lethally irradiated syngeneic recipients (BMT
recipients). WHSC1 BMT recipients had no detectable hematopoietic
phenotype after 1 year of observation using wild-type or tumor-prone
Cdkn2a–/– (Arf/Ink4a-null) (22) mice as bone marrow donors (Supplemental Figure 2 and data not shown). While these negative results
do not exclude the possibility that WHSC1 proteins contribute to
myelomagenesis, they prompted us to reexamine the t(4;14) breakpoint locus at 4p16.3 for an additional oncogenic element.
A noncoding RNA within WHSC1 is overexpressed in t(4;14)-positive
MM and other cancers. To identify additional oncogenes on chromosome 4 in an unbiased fashion, we designed oligonucleotide tiling
arrays spanning the t(4;14) breakpoint region on chromosome 4
(Figure 1A). In samples from patients with MM, expressed RNAs
most significantly associated with t(4;14) status mapped to the
WHSC1 locus (P = 6.33 × 10–5; Table 1). Notably, in addition to

WHSC1 exon sequences, 1 substantial segment mapped to ACA11
(SCARNA22), a 125-bp noncoding RNA (ncRNA) located within
intron 18–19 of WHSC1 (Figure 1, B and C, and Supplemental
Figure 3, A and B). Robust expression of ACA11 was significantly associated with the t(4;14) translocation in MM cell lines and
patient samples (Figure 1, D–F). ACA11 was also overexpressed in
a subset of samples from patients with primary colon, esophageal,
and bladder cancer (Figure 2), consistent with its location within
WHSC1 (16). These data confirm ACA11 overexpression in t(4;14)positive MM, but additional studies are required to confirm the
hypothesis that ACA11 is upregulated in other cancer types.
ACA11 is a box H/ACA snoRNA. The predicted secondary structure
of ACA11 was typical of box H/ACA ncRNAs and revealed 2 hairpin elements connected by a single-stranded hinge carrying the
canonical H box (AnAnnA) followed by a 3′ tail containing the ACA
box (Figure 3A). ACA11 is evolutionarily conserved (Supplemental Figure 3C), but the murine homolog of ACA11 (SCARNA23),
with 82% sequence homology to ACA11, is hosted by a different,
distant gene in mice (Supplemental Figure 3D), consistent with
the categorization of box H/ACA snoRNAs as retroposon-associated mobile genetic elements (23).
Box H/ACA RNAs can accumulate either in nucleoli (i.e., snoRNAs)
or in the nucleoplasmic Cajal bodies (i.e., small Cajal body–specific RNAs [scaRNAs]) (24), and we sought to better classify ACA11
based on its subcellular localization. Using in situ hybridization
followed by immunofluorescence in t(4;14)-positive H929 MM
cells, we found that ACA11 localized to dot-like nuclear structures. Costaining the same cells with a marker of Cajal bodies
demonstrated that the majority of ACA11 RNA did not localize to
Cajal bodies (Figure 3B). On the other hand, we found that ACA11
colocalized with GFP-tagged nucleophosmin (NPM1), a marker of
nucleoli (Figure 3C and ref. 25). To confirm the nucleolar localization of ACA11, stably transfected Arf–/– mouse embryonic fibroblasts (MEFs) were separated into cytoplasmic, nucleoplasmic, and
nucleolar fractions and subjected to Northern blot analysis for
ACA11. ACA11 was predominantly localized to the nucleolar fraction and was not detectable in either cytoplasmic or nucleoplasmic
fractions (Figure 3D). Although these data do not exclude a role
for small amounts of ACA11 in Cajal bodies, based on its predominant nucleolar localization, we classified ACA11 as a snoRNA.
ACA11 binds nucleolar proteins implicated in RNA processing. Box
H/ACA snoRNAs function as guide RNAs for snRNP complexes
(26). To test whether ACA11 physically associates with nuclear proteins, we performed RNA EMSA. The migration of labeled ACA11
RNA was slowed after incubating with H929 cell nuclear extracts,
demonstrating a physical interaction of ACA11 with nuclear proteins (Figure 4A). We then used RNA affinity purification followed
by mass spectrometry (MS) to identify specific protein partners of
ACA11 in t(4;14)-positive MM cells (Figure 4B and Table 2). Using
molecular pathway analysis, most identified proteins that bound to
ACA11 (Supplemental Table 1) were implicated in RNA processing
(Supplemental Table 2), including RNA splicing factors (SF3B1,
SF3B2, and SFPQ), ATP-dependent RNA helicase A (DHX9), RNAspecific adenosine deaminase (ADAR), and 8 members of the heterogeneous nuclear ribonucleoprotein family (HNRNP). Western
blot of RNA affinity-purified lysates confirmed that 9 proteins
identified by MS specifically bound to ACA11 (Figure 4C). Notably, dyskerin and other well-characterized components of the pseudouridylation machinery that comprise other box H/ACA snoRNA
snRNPs (27) were absent from the ACA11 snRNP.
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Table 1
List of tiling array probe segments associated with t(4;14) status in samples from patients with MM
Chr.
4p16.3
4p16.3
4p16.3
4p16.3
4p16.3
4p16.3
4p16.3
4p16.3
4p16.3
4p16.3

Start

Stop

Gene ID

Region

Mean amp.

No.

Length (bp)

1920143
1940066
1976595
1950163
1946890
1976346
1918558
1920919
1920297
1961171

1929297
1940409
1976694
1950295
1947026
1976570
1919898
1921041
1920919
1961639

WHSC1
WHSC1
WHSC1
WHSC1
WHSC1
ACA11
WHSC1
WHSC1
WHSC1
WHSC1

Exon 6
Exon 9
Exon 20
UTR
UTR
Intron 18–19
Exon 5
Intron 6-7
UTR
Exon 18

4,141
3,071
3,057
3,040
2,791
2,494
2,462
2,420
2,273
1,971

8
8
9
8
7
7
16
11
17
21

155
344
100
133
137
225
1341
123
623
469

Top 10 probe regions most significantly associated with t(4;14) (P = 6.33 × 10–5, χ2 = 16). Start and stop are the beginning and end of the segment (in chromosome 4 base pairs) significantly associated with t(4;14). The segment of interest is indicated in bold. Chr., chromosome cytoband; Mean amp., average
probe amplification in arbitrary units; No., number of probes in segment; Length, length of amplified segment.

To confirm association between these proteins and ACA11, we
performed cross-linking immunoprecipitation (CLIP) followed
by RT-PCR. ACA11 RNA was readily detectable in both DHX9
and IL enhancer-binding factor 3 (ILF3) immunoprecipitates in
H929 cells (Figure 4D). We also used immunoprecipitation–Western analysis to evaluate protein-protein interactions within the
ACA11 complex. Endogenous ILF3 was readily identified in DHX9
immunoprecipitates, as were the candidate ACA11-binding proteins nucleolin (NCL), ADAR, and HNRNPU (Figure 4E). These
results were confirmed in a second t(4;14)-positive MM cell line
(LP-1; data not shown). DNA-dependent protein kinase catalytic
subunit (DNA-PK) and SF3B1 immunoreactive bands were less
intense, suggesting weaker or indirect binding to DHX9 (data not
shown). In MM cells, therefore, ACA11 appeared to participate in
a unique snRNP complex composed of at least DHX9, ILF3, NCL,
ADAR, and HNRNPU. Additional studies are required to confirm
the components of this snRNP in live cells.
RNA targets of the ACA11 snRNP include a set of snoRNA intermediates.
To identify RNA substrates of the ACA11 snRNP, we immunoprecipitated ILF3 from H929 cells and subjected isolated RNA to
deep sequencing (Supplemental Figure 4). Among the 50 most
abundant sequences (Supplemental Table 3), the largest number
of sequence reads (626,876) mapped to snoRNA genes (Table 3).
Six of these snoRNAs are positioned within ribosomal protein
(RP) gene hosts. More precisely, these reads uniformly mapped
sharply to the 5′ ends of snoRNA genes, spanned the snoRNAs,
and extended into 3′ intronic and exonic regions of the host RP
genes (Figure 5, A–G). Sequence data were confirmed by RT-PCR
of snoRNA genes in ILF3 and SF3B1 immunoprecipitates in 2 MM
cell lines (Figure 5H). These results suggest that ACA11 snRNP
complexes interact with a set of snoRNA intermediates characterized by sequences partially excised from their host introns at their
5′ end but retaining a 3′ intronic tail.
ACA11 downregulates RP genes without affecting ribosomal biogenesis or
cell growth. At the same time, we sought to identify an mRNA expression signature associated with t(4;14)-positive MM using available
microarray data from 239 patients with MM. We compared the
WHSC1 expression cluster [i.e., t(4;14)] pairwise with 5 other defined
MM expression clusters to identify a prioritized list of gene expression changes specifically associated with t(4;14)-positive myeloma
cases. As expected, the WHSC1 and FGFR3 genes closest to chromo2796

some 4 breakpoints were highly expressed in t(4;14)-positive cases
(Figure 6). Among the total 260 probes, we found 192 probes (111
unique genes) upregulated and 68 probes (50 unique genes) downregulated in t(4;14)-positive cases (Supplemental Table 4). We analyzed
the t(4;14) signature genes using the Kyoto Encyclopedia of Genes
and Genomes database. Strikingly, there was a powerful association
between t(4;14) and downregulation of RP genes (P = 4.8 × 10–20;
Supplemental Table 5) in samples from patients with MM.
snoRNAs function primarily as guide RNAs for the pseudouridylation of ribosomal and spliceosomal RNAs, but additional
roles for this large class of ncRNAs likely remain undiscovered. We
sought to explore the possible role of ACA11 in cancer and began
by determining whether ACA11 expression mediated the downregulation of RP gene transcripts that we observed in t(4;14)-positive
patients with MM. Consistent with the mRNA expression signature
observed (Figure 6), we found that ACA11 expression significantly
suppressed certain RP gene transcripts and steady-state ribosome
protein levels in MEFs (Figure 7, A–D) and in MM cells (Figure 7,
E–H). Intriguingly, however, overexpression of ACA11 did not significantly affect ribosomal subunit assembly (data not shown) or
polysome formation (Supplemental Figure 5A), and ACA11 overexpression did not affect cell volume or cell mass, hallmarks of
ribosomal biogenesis (Supplemental Figure 5, B and C). Recently,
box C/D snoRNAs resident in the RP gene RPL13A were found to
mediate cell death in response to oxidative stress (28). Importantly,
we noted that RPL13A and snoRNA U33 at that locus were downregulated by ACA11 in MM cells (Figure 7, G–I). These findings
lead us to test the effect of ACA11 expression on oxidative stress.
ACA11 modulates oxidative stress responses and contributes to MM cell
proliferation. ACA11 overexpression significantly lowered basal
levels of ROS and suppressed ROS levels following challenge
with hydrogen peroxide (H2O2) in MEFs (Figure 8A). To evaluate its effect in human MM cells, we overexpressed ACA11 in the
t(4;14)-negative MM.1S cell line, and these cells had significantly
reduced ROS levels at baseline and in response to challenge with
peroxide (Figure 8B). Furthermore, overexpression of ACA11
increased proliferation (Figure 8, C and D) and conferred resistance to cytotoxic chemotherapy in t(4;14)-negative MM.1S cells
(Figure 8E). Next, we knocked down ACA11 in t(4;14)-positive
H929 human MM cells using antisense oligonucleotides (ASOs;
Figure 3A, Figure 8, F and G, and Supplemental Figure 6, A–D).
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Figure 2
ACA11 is overexpressed in bladder, colon, and esophageal cancers. (A–C) ACA11 is overexpressed in samples from patients with (A) bladder,
(B) colon, and (C) esophageal cancer. Heat maps of RNA expression at the ACA11 locus were measured using our custom chromosome 4 tiling
arrays. Each bar represents the normalized mean expression value obtained from quadruplicate probes representing each physical location.
Numbers indicate base pairs on chromosome 4 (human genome assembly GRCh37). (D–F) Graphs of data shown in A–C. ACA11 levels in (D)
bladder, (E) colon, and (F) esophagus samples were plotted using raw expression values of 4 probes. Intron, intron 18–19 of WHSC1 upstream
of ACA11. Data in D–F are presented as mean ± SD (n = 4). M, malignant tumor samples. N, normal control samples.

ACA11 knockdown significantly increased ROS production (Figure 8H), decreased cell proliferation as measured by cell counts
and BrdU incorporation (Figure 8, I and J), and sensitized MM
cells to chemotherapy (Figure 8K). Knockdown of ACA11 also
significantly reduced growth of MM tumors in mice (Figure 8,
L–O). Importantly, knockdown of ACA11 did not alter WHSC1-I,
WHSC1-II, or REIIBP protein levels (Supplemental Figure 6E),
but knockout of WHSC1 by other investigators (20) resulted in
loss of ACA11 expression (Supplemental Figure 6F). Knockdown
of ACA11 to undetectable levels in ACA11-low RPMI8226 MM
cells also increased ROS levels, decreased cell proliferation, and

reduced growth of tumors in mice, suggesting that ACA11 functions even at low levels in t(4;14)-negative MM cells (Figure 8, N
and O, and Supplemental Figure 7). These results demonstrate
that ACA11 suppresses oxidative stress, facilitates cell proliferation, and protects cells from the effects of chemotherapy.
Discussion
WHSC1 proteins are consistently expressed as a consequence of the
t(4;14) and are required for the survival of MM cell lines. Surprisingly, we found no phenotype for WHSC1 cDNA isoforms in a range
of overexpression assays. WHSC1 overexpression had no effect on
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Figure 3
ACA11 localizes to nucleoli. (A) Predicted secondary structure of ACA11. Red
brackets indicate H box, ACA box, and CAB motifs. Black lines indicate ASOs.
(B) Endogenous ACA11 is not significantly localized to Cajal bodies (coilin,
red) in MM cells. ACA11 or β-actin is in green; DNA (DAPI) is in blue. Scale bar:
5 μm. (C) Localization of ACA11 to nucleoli. ACA11 or β-actin is shown in red;
NPM1 is shown in green; DNA (DAPI) is in blue. Scale bar: 5 μm. (D) Northern
blot (top 2 panels) for ACA11 in cytoplasmic (CP), nucleoplasmic (NP), and
nucleolar (NS) fractions. Western blot (bottom 3 panels) of cytoplasmic (SOD),
nuclear (NUP62), and nucleolar (NPM1) markers.
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Figure 4
ACA11 binds a noncanonical ribonucleoprotein complex consisting of a set of proteins implicated in RNA processing. (A) RNA EMSA confirming
ACA11 binding to proteins from H929 cell nuclear extracts. Competitor, unlabeled ACA11 RNA. (B) Coomassie-stained SDS-PAGE gel of ACA11
pull-downs used for identification of proteins binding to ACA11 by MS. Representative proteins with the most abundant, unique peptides in each
indicated band are marked with numbers that correspond to those in Table 2. M, protein marker. (C) Confirmation of ACA11-binding proteins by
Western blot. The ACA11-protein complex was purified as in B and subjected to Western blot with antibodies to proteins identified by MS. The
asterisk indicates nonspecific binding. Hsp90 was used as a negative control. (D) Confirmation of ACA11 presence in a DHX9/ILF3 ribonucleoprotein complex by CLIP followed by RT-PCR using H929 cells. H2O was used as a water template for RT-PCR. GAPDH was used as an internal
control. M, DNA marker. (E) Physical interaction of ACA11 ribonucleoprotein complex proteins NCL, ILF3, ADAR, and HNRNPU with DHX9 in
H929 cells was confirmed by immunoprecipitation.

proliferation either in lymphoid Ba/F3 or immortalized NIH/3T3
cells (Supplemental Figure 1). Similarly, we found no phenotype in
Eμ-WHSC1-I, WHSC1-II, or REIIBP transgenic mice or in wild-type
murine bone marrow transduction-transplantation (BMT) experiments. Unpublished studies suggest that WHSC1 overexpression
in primary B cells may have cell death-promoting effects (P. Leif
Bergsagel, unpublished observations), and the potential toxicity of
WHSC1 was the rationale for our use of Cdkn2a knockout (null for
both Ink4a and Arf) mice as bone marrow donors in follow-up BMT
experiments. Using tumor-prone, apoptosis-resistant Cdkn2a–/–
mice as bone marrow donors, we overexpressed WHSC1 isoforms in
primary hematopoietic cells (Supplemental Figure 2D). However,
even in this permissive genetic background, none of the WHSC1
isoforms perturbed normal hematopoiesis (Supplemental Figure
2). Negative results do not exclude an important role for WHSC1
proteins in MM cell transformation, but they stimulated our search
for a missing ingredient in t(4;14) biology. We analyzed transcripts
deregulated by the t(4;14) at the 4p16.3 locus in an unbiased fashion
using expression tiling arrays and uncovered what we believe to be
a new piece to the puzzle: a snoRNA embedded within the WHSC1
locus. ACA11 is a small (125-bp) nucleolar-localized RNA (i.e.,
snoRNA), with a double-hairpin structure and box H and box ACA

domains (Figure 3A). Box H/ACA snoRNAs play roles in splicing
and ribosome biogenesis by guiding the pseudouridylation of spliceosomal and ribosomal RNAs, but ACA11 is an orphan snoRNA
with no known RNA target.
Using custom tiling arrays, we detected the expression of ACA11
in MM and other cancers in a pattern consistent with the physical
linkage of this snoRNA to WHSC1 (Figure 1, B and C, and Figure 2).
We confirmed ACA11 expression in MM cell lines using Northern
blots (Figure 1E). We also developed a quantitative real-time PCR
(qRT-PCR) assay for ACA11 using 3 housekeeping gene controls
to accurately measure ACA11 levels in 11 cell lines and 63 samples
from patients with MM (Figure 1, D and F). ACA11 was significantly
associated with t(4;14) in MM cell lines (P = 0.0167) and in patients
with MM (P < 0.0001). Despite this strong association, ACA11
was overexpressed in some t(4;14)-negative cell lines and patient
samples, which we did not find surprising. Up to 25% of t(4;14)negative cases upregulate WHSC1 transcripts to the same level as
that in t(4;14)-positive cases (14, 29), suggesting that WHSC1 is
deregulated by mechanisms besides t(4;14). Furthermore, WHSC1
is overexpressed in neuroblastoma, colon, esophageal, and bladder
cancers that do not harbor the t(4;14) (14–16). ACA11 overexpression in primary bladder, colon, and esophageal cancer samples sug-
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Table 2
Representative proteins with most unique peptides
No.
1
2
3
4
5
6
7

8
9
10
11
12
13
14
15
16
17
18

Proteins names and abbreviations
DNA-dependent protein kinase catalytic subunit (DNA-PK)
Myb-binding protein 1A (MYBBP1A)
Splicing factor 3B subunit 1 (SF3B1)
ATP-dependent RNA helicase A (DHX9)
SWI/SNF-related matrix-associated actin-dependent regulator
of chromatin subfamily A member 5 (SMARCA5)
RNA-specific adenosine deaminase (ADAR)
Heterogeneous nuclear ribonucleoprotein U (HNRNPU)
IL enhancer-binding factor 3 (ILF3)
Nucleolin (NCL)
Pre-mRNA-processing factor 6 (PRPF6)
Nucleolar RNA helicase 2 (DDX21)
Far upstream element-binding protein 2 (KHSRP)
Heterogeneous nuclear ribonucleoprotein R (HNRNPR)
Heterogeneous nuclear ribonucleoprotein M (HNRNPM)
Guanine nucleotide-binding protein-like 3 (GNL3)
Prelamin-A/C (LMNA)
Heterogeneous nuclear ribonucleoprotein L (HNRNPL)
Heterogeneous nuclear ribonucleoprotein K (HNRNPK)
Polypyrimidine tract-binding protein 1 (PTBP1)
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1)
IL enhancer-binding factor 2 (ILF2)
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)

Numbers correspond with those in Figure 4B.

gests a potential role for ACA11 in nonhematopoietic tumors (Figure 2). Activation of ACA11 by more than one mechanism may be
considered a sign of its importance to tumor biology.
We confirmed by confocal microscopy and cell fractionation
studies that ACA11 localized predominantly to cell nucleoli in
MEF cells overexpressing ACA11 (Figure 3D). snoRNAs are nucleolar-localized ncRNAs, which serve as template guides for the
posttranscriptional modification of target ribosomal and spliceosomal RNAs (24). We can not exclude the possibility that during
normal development endogenous ACA11 might localize to Cajal
bodies (i.e., and be categorized as a scaRNA), but in this setting our
data categorize ACA11 as a snoRNA. After the telomerase RNA
subunit, ACA11 is the only the second box H/ACA class snoRNA
to our knowledge with a role in cancer and the first to be directly
activated in cancer by chromosomal translocation.
We found ACA11 to be a component of a novel snRNP complex.
Box H/ACA snoRNAs function primarily as guide RNAs for the dyskerin snRNP complex responsible for pseudouridylation of ribosomal RNAs (27). MS analysis of ACA11-binding proteins revealed
a cohort of proteins distinct from the canonical box H/ACA
snoRNA-binding proteins: SF3B1, RNA helicase A, ADAR, and several members of the heterogeneous nuclear ribonucleoprotein family (HNRNPR, HNRNPL, HNRNPM, HNRNPK, and HNRNPU;
Figure 4B and Table 2). We confirmed ACA11 interaction with 5
highly expressed proteins by Western blotting of ACA11 snoRNA
pull-downs (Figure 4, C–E). We did not find any protein components of the dyskerin snRNP binding to ACA11 in MM cells.
Instead, the ACA11 snRNP appears to be a novel complex involved
in regulation of RNA processing. Deep sequencing experiments
revealed an unusual species of RNA, consisting of partially processed snoRNAs (Figure 5 and Table 3). We propose that the ACA11
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snRNP is required for the 3′ processing of select snoRNAs. Additional work will be required to characterize the biochemistry of this
snRNP and the targets that may be relevant to cancer biology.
Gene targeting at the human WHSC1 locus must be performed
with caution, because ACA11 expression is coupled to that of
WHSC1. ACA11 knockdown by ASOs did not affect WHSC1 protein levels, but ACA11 expression was drastically reduced in KMS-11
MM cells with WHSC1 knocked out by homologous recombination
(TKO1 and TKO2 cells; Supplemental Figure 6, E and F). Kuo et al.
(18) recently used KMS-11 and TKO2 cells as a foundation to identify target genes of WHSC1 and proposed that WHSC1 HMT activity activates an oncogenic program. These authors first compared
gene expression profiles of KMS-11 cells (WHSC1 intact) and TKO2
cells (WHSC1 deleted) as an initial screen for WHSC1 target genes,
but TKO2 cells are in fact knocked out for ACA11 as well, not just
WHSC1. These authors used WHSC1 cDNA constructs (i.e., without
ACA11) to demonstrate the specificity of HMT regulation of specific
oncogenes (e.g., TGFA and MET), but it remains unclear which HMTinduced genes contribute to t(4;14)-positive MM disease behavior.
Kuo also demonstrated that WHSC1 cDNAs transformed primary
Arf-null fibroblasts (MEFs), which we cannot reconcile with our data
except to say that we used different assays for transformation (BMT
compared with methylcellulose). WHSC1 expression certainly plays
an important role in t(4;14)-mediated transformation. We propose
that WHSC1 and ACA11 are 2 distinct cancer genes encoded at the
same locus, much as Arf and Ink4a are both encoded by the Cdkn2a
locus. Future studies of WHSC1 effects in tumor biology should
take into account the fact that ACA11 is a distinct entity within the
WHSC1 locus that can significantly affect cell behavior.
We found that a major component of the t(4;14) mRNA expression profile in samples from patients with MM, i.e., downregulation of RP genes (Figure 6), can be attributed to ACA11 expression.
Downregulation of RP genes has been observed in patients with
MM by other investigators but without explanation (30). Genes
involved in protein biosynthesis, including RP genes, are relatively
upregulated in hyperdiploid MM due to chromosomal copy number abnormalities (31), but the RP gene signature that we observed
is unlikely due simply to nonhyperdiploidy, because we used
recursive analysis to identify a gene signature specifically associated with t(4;14). We demonstrated that ACA11 was sufficient to
downregulate a handful of t(4;14)-associated RP genes (Figure 7).
We assessed the downstream effects of ACA11 on ribosome function by testing polysome formation, cell growth, and cell volume
but found no significant changes upon overexpression of ACA11
Table 3
Summary of deep sequencing data
Category
snoRNAsA
RNP components
Pseudogenes
Histone genes
Other

Genes

Total tags

22
7
4
3
14

626,876
110,071
226,355
16,319
444,610

The top 50 RNAs bound to ILF3 listed by total number of sequencing
tags and divided into major categories. The largest number of reads
mapped to snoRNA loci. RNP components include spliceosomal noncoding snRNP RNAs, including U5 and U3. Total tags, the total number
of sequencing reads mapped back to each peak. ASix snoRNAs in this
category mapped to RP host genes.
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Figure 5
RNA targets of the ACA11 ribonucleoprotein complex identified by RNP immunoprecipitation and deep sequencing. (A–F) Graphical representation of sequencing peaks mapping to the 6 targets of ACA11 snRNP. The horizontal gray bars indicate the locations of snoRNAs visualized in the
UCSC genome browser. Arrows represent primers used for RT-PCR in H. (G) The same data as in E shown with lower vertical scale demonstrate
smaller peaks of RPL10 exons. (H) RT-PCR confirms the presence of the indicated snoRNA intermediates resident within RP genes in the ILF3-,
SF3B1-, or control IgG-precipitated complexes from H929 cells. H2O was used as a water template. GAPDH was used as control.

(Supplemental Figure 5). Rather, as revealed by deep sequencing
of ACA11 snRNP RNAs, the molecular targets of ACA11 appear
to be snoRNAs, hosted within RP genes. Recently, RPL13A and its
resident snoRNAs were found to mediate ROS (28), and we found
that ACA11 expression protected cells from oxidative stress and
cytotoxic chemotherapy. We used 3 MM cell lines for functional
studies, including the MM.1S cell line, which expresses ACA11 at
very low levels. Forced expression of ACA11 in MM.1S cells reduced
ROS levels, increased proliferation, and significantly protected the
cells from cytotoxic chemotherapy (Figure 8, B–E). Knockdown
of ACA11 significantly affected the proliferation, BrdU incorporation, and ROS levels in both t(4;14)-positive H929 and t(4;14)negative RPMI8226 cells, and these biologic effects were consistently matched with the degree of knockdown achieved (Figure 8,
F–K, and Supplemental Figure 7). Real-time PCR assays for ACA11
expression found that in fact RPMI8226 cells expressed ACA11 at

readily detectable levels, and ASO knockdown significantly reduced
ACA11 levels in these cells. The consistent functional effects we
observed using both ACA11 overexpression and well-controlled
ASO knockdowns make the possibility of off-target ASO effects
unlikely. Mateescu et al. (32) recently demonstrated that miR-200
family members miR-141 and miR-200a increase ROS and sensitivity to chemotherapy via p38a in ovarian cancer. ACA11 provides
essentially the opposite effect, i.e., suppression of ROS and protection of cells from chemotherapy (Figure 8, B, E, H, and K).
We believe that ACA11 is a novel element of t(4;14) biology. Does
ACA11 by itself cause MM? We doubt that ACA11 overexpression
alone will be sufficient to induce disease. The t(4;14) is found in
patients with premalignant monoclonal gammopathy of undetermined significance at rates comparable to those seen in patients
with MM, suggesting that the t(4;14) itself is likely an early event
in MM pathogenesis that alone is insufficient to cause MM. Fur-
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Figure 6
A t(4;14) gene expression signature defined by mRNA expression microarray data from 239 samples from patients with myeloma. WHSC1 is
upregulated in all 4p16 patients (arrow), and the nearby FGFR3 gene (arrow) is upregulated in most but not all 4p16 patients. Previously defined
patient subgroup clusters (see Methods) are indicated by orange, dark green, red, dark blue, light green, and light blue. Highly significant downregulation (**P = 4.8 × 10–20) of RP genes was found in the 4p16 (i.e., WHSC1, orange) subgroup.
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Figure 7
ACA11 provides evidence for the t(4;14) gene signature in part — ACA11 is sufficient to downregulate RP genes. (A) Overexpression of ACA11
confirmed by Northern blot analysis in Arf–/– MEFs stably transduced with ACA11 lentiviruses. β-Actin was used as loading control. (B) Overexpression of ACA11 in Arf–/– MEFs as measured by qRT-PCR. (C) RP mRNA expression in Arf–/– MEFs overexpressing ACA11 was analyzed by
qRT-PCR. (D) Expression of RPs in Arf–/– MEFs overexpressing ACA11 demonstrated by Western blot. γ-Tubulin was used as loading control. (E)
Overexpression of ACA11 confirmed by Northern blot analysis in MM.1S cells stably transduced with ACA11 lentiviruses. β-Actin was used as
loading control. (F) qRT-PCR showing the expression of ACA11 in MM.1S cells in E. (G) RP mRNA expression in MM.1S cells overexpressing
ACA11 was analyzed by qRT-PCR. (H) Downregulation of RPs in MM.1S cells overexpressing ACA11 demonstrated by Western blot. γ-Tubulin was
used as loading control. (I) Small RNAs were isolated from MM.1S cells overexpressing ACA11. snoRNA expression was analyzed by qRT-PCR.
U43, snoRNA located in RPL3; U64, snoRNA located in RPS2; U32A, U33, and U35A, snoRNAs located in RPL13A. qRT-PCR data were normalized to the average of 3 reference genes, (B, C, F, and G) GAPDH, UBC, and YWHAZ or (I) U6, U44, and U48, and are shown as fold change
relative to that of mock-treated cells. Data represent mean ± SD (n = 3). *P < 0.05, **P < 0.01.

thermore, 85% percent of t(4;14)-positive MM cases also harbor
chromosome deletions that affect an unidentified tumor suppressor gene on chromosome 13, suggesting that additional mutations
are required for disease development. Conclusive demonstration
of the role of ACA11 in MM pathogenesis will likely require the
development of mouse models with complex genetics. An intriguing possibility is that WHSC1 proteins and the ACA11 snoRNA
cooperate in MM pathogenesis. Taken together, our findings demonstrate that ACA11 is a functionally important component of the
t(4;14) translocation. Detection and/or pharmaceutical targeting
of ACA11 may be useful in cancer patient care.

Methods
Patient samples. RNAs from CD138-positive bone marrow cells of patients with
MM were used for analysis. The t(4;14)-positive samples were assessed by FISH
assay on whole bone marrow or CD138-enriched cells. Seven bladder, eight
colon, and eight esophagus cancer and normal tissue control RNA samples
were obtained anonymously from the Tissue Procurement Core Facility and
Tumor Bank of Washington University in St. Louis, St. Louis, Missouri, USA.
Gene expression analysis. We analyzed the Multiple Myeloma Research Consortium data set (GSE26760) of gene expression profiles of 239 patients with
Affymetrix U133Plus2 platform, including 53 cases of 11q13, 25 cases of 4p16,
4 cases of 6p21, 77 cases of cyclin D1, 39 cases of cyclin D2, 13 cases of D1+D2,
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Figure 8
ACA11 functions to modulate oxidative stress, cell proliferation, and resistance to chemotherapy. (A and B) ROS levels, quantified by DCFH-DA
(DCF) labeling, are suppressed by ACA11 expression in (A) Arf–/– MEFs
or (B) MM.1S cells at baseline and upon challenge with hydrogen peroxide (H2O2). (C and D) ACA11 expression increased growth and proliferation of MM.1S cells as measured by (C) cell counting and (D) BrdUELISA relative to mock-treated cells. (E) ACA11 increased resistance of
MM.1S cells to cytotoxic chemotherapy as measured by MTT viability
assay. (F and G) Northern blot and qRT-PCR analyses of ACA11 knockdown in H929 cells 4 days after transfection with ASOs. β-Actin was used
as loading control. U23, unrelated snoRNA. αA2 and αA3 are ASOs that
target ACA11. (H–K) Knockdown of ACA11 in H929 cells (H) increased
ROS levels, (I) decreased cell growth, (J) decreased cell proliferation,
and (K) decreased resistance to cytotoxic chemotherapy. (L and N)
Growth of (L) KMS-11 and (N) RPMI8226 cells in immunocompromised
mice is reduced by ACA11 knockdown. (M and O) qRT-PCR showing
the expression of ACA11 in (M) KMS-11 and (O) RPMI8226 xenograft
tumors. Cells were nucleofected with 600 pmol ASOs per 106 cells and
cultured for (I) 24 hours or (H, J–L, and N) 48 hours before further analysis. qRT-PCR data in G, M, and O were normalized to the average of 3
reference genes (GAPDH, UBC, YWHAZ) and are shown as fold change
relative to that of mock-treated cells. All data shown represent mean ± SD
(n = 3 [A–E and G–K], n = 5 [L–O]). *P < 0.05, **P < 0.01.

15 cases of MAF, and 13 cases defined as “None” (which refers to cases that
did not fall into the 7 defined expression groups). The raw data were preprocessed by robust multichip average normalization, and the analysis was conducted using Bioconductor 2.8 under R 2.11. Using significance analysis of
microarrays, we performed a one-to-one comparison between 4p16 (WHSC1)
and the other 5 major subtypes (D1, D1+D2, D2, 11q13, and MAF [6p21
and None were excluded due to the small sample sizes]), with a cutoff false
discovery rate q value of less than 0.1. The resulting 5 lists (see Supplemental
Table 4) were further intersected to find the genes consistently upregulated
(or downregulated) specifically to WHSC1 subtype. Hypergeometric tests were
performed using the Kyoto Encyclopedia of Genes and Genomes database.
The data set was updated to 304 samples on May 23, 2011.
Tiling array design and hybridization. Custom arrays with 12 identical sections
were manufactured by NimbleGen. Each section contained 60-bp probes spanning the entire region of chromosome 4, from 1.642 Mb to 2.072 Mb, including both forward and reverse strands. Ten housekeeping genes covered by ten
probes each served as controls. Every experimental and housekeeping probe
was used in quadruplicate as an additional control. Five μg of total cellular
RNAs were polyadenylated using Plus Module 10 Assay (Genisphere) according to the manufacturer’s protocol. Double-stranded cDNA was created using
the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen). cDNA was
then labeled with a DNA Labeling Kit (NimbleGen) and subsequently hybridized to a NimbleGen array using the NimbleGen Hybridization System. Data
were analyzed using Partek Genomics Suite software. The overall expression
profile of the region of interest was generated from the median values of the
raw expression values of the quadruplicate tiling probes. Tiling array data have
been deposited into NCBI GEO (GSE36685; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=lhmpnoycusyqytq&acc=GSE36685).
RNA secondary structure prediction. RNA secondary structure was predicted using the Vienna RNA package (version 2.0.0, Theoretical Biochemistry Group), based on the minimum free energy algorithm of
Zuker and Stiegler (33).
Plasmid constructs and virus production. The coding region of ACA11 was
amplified from human genomic DNA and subcloned to pBluescript II KS
(+) vector (Stratagene) (pBS-ACA11) or lentiviral vector FCY-si. Lentivirus
(FCY-ACA11-YFP) was generated by recombination as described in the
Supplemental Methods.

RT-PCR and qRT-PCR. Total RNAs were extracted using TRIzol (Invitrogen)
reagent, and small RNAs were isolated using a mirVana miRNA Isolation Kit
(Ambion) and treated with RNase-free DNase I (Invitrogen) according to the
manufacturer’s protocol. RT-PCR was performed according to the protocol
of the SuperScript One-Step RT-PCR with Platinum Taq Kit (Invitrogen).
qRT-PCR was performed using the iScript One-Step RT-PCR Kit with SYBR
Green (Bio-Rad) or custom TaqMan small RNA assays (Applied Biosystems)
for quantification of snoRNAs on the Miniopticon system (Bio-Rad) following the manufacturer’s protocol. GAPDH, UBC, YWHAZ, U6, U44, and U48
were used as reference genes. Quantitative data were analyzed using Qbaseplus
software (Biogazelle). Each assay was performed in triplicate. Primer
sequences are provided in Supplemental Table 6.
Northern blot. Total RNA was denatured, fractionated by electrophoresis, transferred to a nylon membrane (Amersham), and fixed by UV crosslinking. The RNA blots were hybridized to 32P-labeled probes specific for
ACA11 as previously described (34) or the biotin-labeled probes using the
BrightStar BioDetect Kit (Ambion) according to the manufacturer’s protocol. The antisense biotin-labeled RNA probe was synthesized by in vitro
transcription with T7 RNA polymerase (MAXIscript Kit, Ambion).
FISH and immunofluorescence. FISH assay was performed according to the
protocol of R. Singer (http://singerlab.org/protocols). Fluorescein-labeled
(Roche) or cyanine-labeled (PerkinElmer) RNA probes were used. p80-coilin was detected with monoclonal mouse anti-coilin and rhodamine-conjugated anti-mouse antibody (Abcam). Cell nuclei were visualized with DAPI.
Images were acquired on a confocal microscope (Olympus, FV1000).
RNA EMSA and RNA affinity chromatography. We performed RNA EMSA
and RNA affinity chromatography as described in the Supplemental Methods. Briefly, the 3′ end biotinylated sense RNA was incubated with native
nuclear protein extracts and the EMSA binding buffer. The RNA-protein
complexes were subjected to a nondenaturing polyacrylamide gel for EMSA
analysis or purified using the high-capacity streptavidin agarose resin
(Pierce), followed by resolving on a SDS-PAGE gel for further MS analysis.
MS. Electrospray-linear ion trap and Fourier transform ion cyclotron
MS (LTQ FT, Thermo-Finnigan) was performed as described previously
(35). Database searching was performed using a UniProt database selected for Homo sapiens (downloaded on 12/6/2010, 97,048 entries). Scaffold
(Proteome Software Inc.) was used to validate MS/MS-based peptide and
protein identifications. Peptide and protein identifications were accepted
if they could be established at greater than 95.0% probability as specified
by the Peptide Prophet algorithm (36, 37). Molecular network analysis was
performed using the IPA software (Ingenuity Systems).
Immunoprecipitation and Western blot. Immunoprecipitation and Western
blot were performed as described previously (38). Antibodies are described
in the Supplemental Methods.
Cross-linking ribonucleoprotein immunoprecipitation and RNA sequencing. CLIP
was performed as described previously (39). The isolated RNA fragments
were ligated to Illumina adaptors, followed by RT and PCR amplification.
The prepared libraries were sequenced on the Illumina HiSeq 2000 platform.
The model-based analysis for ChIP-Seq (MACS) algorithm was used for analysis. Detailed procedures are described in the Supplemental Methods.
ROS detection. 2′,7′-dichlorof luorescein diacetate (DCFH-DA,
Sigma-Aldrich) was used to measure ROS generation. Fluorescence intensity was quantified using a microplate fluorometer (BioTek) or flow cytometry (BD) as described previously (28).
snoRNA knockdown. Chemically modified ASOs were used for knockdown experiments, as described in the Supplemental Methods. ASOs targeting GFP served as a control.
Cell growth, cell volume, cell mass, and proliferation assays. Cell growth curves
were performed during 6 days of culture. Cell mass was measured by Bradford assay (Bio-Rad), and cell volume was measured as described previously
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(25). Cell proliferation was detected using the Cell Proliferation ELISA
BrdU (colorimetric) Kit (Roche) according to the manufacturer’s instructions or the MTT assay (Sigma-Aldrich).
Chemotherapy resistance assays. Cells were incubated with different doses of
doxorubicin (Sigma-Aldrich) at the indicated concentrations (see Figure 8,
E and K) or 50 μg/ml 5-fluorouracil (Sigma-Aldrich). Cellular viability was
assessed by MTT assay after 44 hours of incubation or trypan blue exclusion assay. Experiments were repeated 3 times.
Statistics. Data are shown as mean ± SD unless noted otherwise. Twotailed unpaired Student’s t test and 1-way ANOVA with a Bonferroni posthoc test were carried out using Prism (GraphPad Software). P < 0.05 was
considered significant.
Study approval. Studies with human samples were approved by the
human research protection office at Washington University in St. Louis,
and informed consent from the patients was obtained in accordance with
the Declaration of Helsinki. Animal studies were approved by the Animal
Study Committee at Washington University in St. Louis.

Acknowledgments
We thank Michael Heinz, Paul Cliften, and the Genome Technology Access Center (GTAC) in the Department of Genetics for help
1. Palumbo A, Anderson K. Multiple myeloma. N Engl
J Med. 2011;364(11):1046–1060.
2. Richelda R, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma
involves the fibroblast growth-factor receptor 3
gene. Blood. 1997;90(10):4062–4070.
3. Chesi M, et al. Frequent translocation t(4;14)
(p16.3;q32.3) in multiple myeloma is associated
with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat
Genet. 1997;16(3):260–264.
4. Winkler JM, Greipp P, Fonseca R. t(4;14)
(p16.3;q32) is strongly associated with a shorter
survival in myeloma patients. Br J Haematol. 2003;
120(1):170–171.
5. Karlin L, et al. Clinical and biological features of
t(4;14) multiple myeloma: a prospective study. Leuk
Lymphoma. 2011;52(2):238–246.
6. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl
WM, Bergsagel PL. The t(4;14) translocation in
myeloma dysregulates both FGFR3 and a novel
gene, MMSET, resulting in IgH/MMSET hybrid
transcripts. Blood. 1998;92(9):3025–3034.
7. Garlisi CG, et al. A unique mRNA initiated within a
middle intron of WHSC1/MMSET encodes a DNA
binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol. 2001;24(1):90–98.
8. Marango J, et al. The MMSET protein is a histone
methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111(6):3145–3154.
9. Pei H, et al. MMSET regulates histone H4K20
methylation and 53BP1 accumulation at DNA
damage sites. Nature. 2011;470(7332):124–128.
10. Martinez-Garcia E, et al. The MMSET histone
methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple
myeloma cells. Blood. 2011;117(1):211–220.
11. Nimura K, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature. 2009;460(7252):287–291.
12. Kim JY, et al. Multiple-myeloma-related WHSC1/
MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol
Cell Biol. 2008;28(6):2023–2034.
13. Hajdu I, Ciccia A, Lewis SM, Elledge SJ. WolfHirschhorn syndrome candidate 1 is involved in

2806

with genomic analysis and Shashi Kulkarni and members of his laboratory for assistance with RNA FISH. We thank Michael Kuchenreuther for technical assistance. Mark Fiala coordinated the myeloma tissue sample bank at Washington University. The authors wish
to thank Kathy Weilbaecher, John Dipersio, and Jason Weber for
helpful discussions. This work was funded by the Multiple Myeloma Research Foundation (to M.H. Tomasson), the Barnes-Jewish
Hospital Foundation (to M.H. Tomasson), and a NMRC Clinician
Scientist Award (to W.J. Chng). GTAC is partially supported by NCI
Cancer Center support grant P30 CA91842 to the Siteman Cancer
Center and by ICTS/CTSA grant UL1RR024992 from the National
Center for Research Resources, a component of the NIH. We would
especially like to thank our patients.
Received for publication January 25, 2012, and accepted in revised
form May 2, 2012.
Address correspondence to: Michael H. Tomasson, Washington
University School of Medicine, Campus Box 8069, 660 South Euclid
Avenue, St. Louis, Missouri 63110, USA. Phone: 314.362.9350; Fax:
314.747.2797; E-mail: tomasson@dom.wustl.edu.

the cellular response to DNA damage. Proc Natl
Acad Sci U S A. 2011;108(32):13130–13134.
14. Hudlebusch HR, et al. The histone methyltransferase and putative oncoprotein MMSET is
overexpressed in a large variety of human tumors.
Clin Cancer Res. 2011;17(9):2919–2933.
15. Hudlebusch HR, et al. MMSET is highly expressed
and associated with aggressiveness in neuroblastoma. Cancer Res. 2011;71(12):4226–4235.
16. Kassambara A, Klein B, Moreaux J. MMSET is
overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun. 2009;
379(4):840–845.
17. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98NSD1 links H3K36 methylation to Hox-A gene
activation and leukaemogenesis. Nat Cell Biol. 2007;
9(7):804–812.
18. Kuo AJ, et al. NSD2 links dimethylation of histone
H3 at lysine 36 to oncogenic programming. Mol
Cell. 2011;44(4):609–620.
19. Toyokawa G, et al. Histone lysine methyltransferase
Wolf-Hirschhorn syndrome candidate 1 is involved
in human carcinogenesis through regulation of the
Wnt pathway. Neoplasia. 2011;13(10):887–898.
20. Lauring J, et al. The multiple myeloma associated
MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008;
111(2):856–864.
21. Keats JJ, et al. Overexpression of transcripts originating from the MMSET locus characterizes
all t(4;14)(p16;q32)-positive multiple myeloma
patients. Blood. 2005;105(10):4060–4069.
22. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D,
DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85(1):27–37.
23. Weber MJ. Mammalian small nucleolar RNAs
are mobile genetic elements. PLoS Genet. 2006;
2(12):e205.
24. Kiss T, Fayet E, Jady BE, Richard P, Weber M. Biogenesis and intranuclear trafficking of human
box C/D and H/ACA RNPs. Cold Spring Harb Symp
Quant Biol. 2006;71:407–417.
25. Maggi LB Jr, et al. Nucleophosmin serves as a ratelimiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol. 2008;28(23):7050–7065.
26. Kiss T, Fayet-Lebaron E, Jady BE. Box H/ACA small

ribonucleoproteins. Mol Cell. 2010;37(5):597–606.
27. Kiss AM, Jady BE, Bertrand E, Kiss T. Human box
H/ACA pseudouridylation guide RNA machinery.
Mol Cell Biol. 2004;24(13):5797–5807.
28. Michel CI, et al. Small nucleolar RNAs U32a, U33,
and U35a are critical mediators of metabolic stress.
Cell Metab. 2011;14(1):33–44.
29. Dring AM, et al. A global expression-based analysis
of the consequences of the t(4;14) translocation in
myeloma. Clin Cancer Res. 2004;10(17):5692–5701.
30. Chapman MA, et al. Initial genome sequencing
and analysis of multiple myeloma. Nature. 2011;
471(7339):467–472.
31. Chng WJ, et al. Molecular dissection of hyperdiploid
multiple myeloma by gene expression profiling.
Cancer Res. 2007;67(7):2982–2989.
32. Mateescu B, et al. miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative
stress response. Nat Med. 2011;17(12):1627–1635.
33. Zuker M, Stiegler P. Optimal computer folding
of large RNA sequences using thermodynamics
and auxiliary information. Nucleic Acids Res. 1981;
9(1):133–148.
34. Yu Y, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 2006;
26(10):3798–3809.
35. Mendelsohn BA, Malone JP, Townsend RR, Gitlin
JD. Proteomic analysis of anoxia tolerance in the
developing zebrafish embryo. Comp Biochem Physiol
Part D Genomics Proteomics. 2009;4(1):21–31.
36. Keller A, Nesvizhskii AI, Kolker E, Aebersold R.
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and
database search. Anal Chem. 2002;74(20):5383–5392.
37. Nesvizhskii AI, Keller A, Kolker E, Aebersold R.
A statistical model for identifying proteins by
tandem mass spectrometry. Anal Chem. 2003;
75(17):4646–4658.
38. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH.
Neoplasia driven by mutant c-KIT is mediated by
intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007;27(1):267–282.
39. Niranjanakumari S, Lasda E, Brazas R, GarciaBlanco MA. Reversible cross-linking combined
with immunoprecipitation to study RNA-protein
interactions in vivo. Methods. 2002;26(2):182–190.

The Journal of Clinical Investigation    http://www.jci.org   Volume 122   Number 8   August 2012

